Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Atherosclerotic Cardiovascular Risk”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT06692764
What this trial is testing

Assess the Effect of AZD0780 on Ambulatory Blood Pressure

Who this might be right for
Atherosclerotic Cardiovascular Disease
AstraZeneca 202
Not applicableStudy completedNCT03702764
What this trial is testing

Coronary Plaque Geometry and Acute Coronary Syndromes

Who this might be right for
Coronary StenosisAcute Coronary SyndromeAcute Myocardial Infarction+2 more
Cardio Med Medical Center 1,000
Not applicableUnknownNCT02388412
What this trial is testing

18F-NaF-PET for Identification of TCFA

Who this might be right for
Acute Coronary Syndrome
Seoul National University Hospital 96
Not applicableLooking for participantsNCT07301489
What this trial is testing

Akershus Cardiac Examination (ACE) 5 Study

Who this might be right for
Heavy SmokersLung Cancer ScreeningCardiovascular Risk Profile+1 more
University Hospital, Akershus 1,000
Not applicableUnknownNCT02257333
What this trial is testing

Retinal Thrombosis and Atherosclerosis

Who this might be right for
Retinal Vein Occlusion
University of Roma La Sapienza 1,000
Not applicableNot Yet RecruitingNCT07615296
What this trial is testing

Target-Oriented Strategy of Ultra-Low LDL-C (<1.0 vs. 1.0-1.39 mmol/L) in Extreme-High-Risk ASCVD Patients: Clinical Benefit, Safety and Cost-Effectiveness Assessment

Who this might be right for
Atherosclerotic Cardiovascular Disease (ASCVD)
Beijing Anzhen Hospital 6,000
Not applicableStudy completedNCT00316108
What this trial is testing

Boston Scientific Embolic Protection, Inc. (EPI): A Carotid Stenting Trial for High-Risk Surgical Patients (BEACH)

Who this might be right for
Carotid Artery DiseasesStrokeCerebral Arteriosclerosis
Boston Scientific Corporation 747
Not applicableStudy completedNCT00738725
What this trial is testing

BioImage Study: A Clinical Study of Burden of Atherosclerotic Disease in an At-Risk Population

Who this might be right for
PlaqueAtherosclerotic DiseaseHeart Disease+1 more
BG Medicine, Inc 7,687
Post-approval studies (Phase 4)Enrolling By InvitationNCT05579626
What this trial is testing

Comparison of Low-Intensity Statin Plus Ezetimibe Versus High-Intensity Statin Therapy on Risk of New-Onset Diabetes Mellitus (PROVE-DM)

Who this might be right for
Pre DiabetesASCVD
Seung-Whan Lee, M.D., Ph.D. 4,000
Large-scale testing (Phase 3)Active Not RecruitingNCT06292013
What this trial is testing

Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Who this might be right for
Atherosclerotic Cardiovascular Disease (ASCVD)Elevated Lp(a)
Eli Lilly and Company 17,300
Post-approval studies (Phase 4)Ended earlyNCT00651378
What this trial is testing

Switching to Rosuvastatin Versus Adding Ezetimibe to Atorvastatin Versus Doubling the Dose of Atorvastatin in Patients With Hypercholesterolemia and Risk Factors (P03708)

Who this might be right for
HypercholesterolemiaAtherosclerosisCoronary Artery Disease
Organon and Co 87
Large-scale testing (Phase 3)Active Not RecruitingNCT05739383
What this trial is testing

Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

Who this might be right for
Primary Prevention of Atherosclerotic Cardiovascular Disease
Novartis Pharmaceuticals 14,012
Not applicableUnknownNCT05639218
What this trial is testing

Impact of Optimal Pharmacotherapy on Lipid Profile and Qualitative Features of Atherosclerotic Plaques

Who this might be right for
Atherosclerotic Cardiovascular Disease
Pauls Stradins Clinical University Hospital 50
Testing effectiveness (Phase 2)Looking for participantsNCT06488105
What this trial is testing

Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders Trial

Who this might be right for
Lipid DisorderHypercholesterolemiaCardiovascular Diseases+1 more
Wake Forest University Health Sciences 130
Not applicableStudy completedNCT03225196
What this trial is testing

Extracellular RNAs in Relation to Cardiometabolic Risk

Who this might be right for
Subclinical Atherosclerotic Cardiovascular DiseaseBlood PressureObesity
National Heart, Lung, and Blood Institute (NHLBI) 4,495
Not applicableStudy completedNCT01808729
What this trial is testing

CAUSE Trial: Patient Specific-Cellular Characterization of Fibromuscular Dysplasia and High-Risk Atherosclerotic Endothelium

Who this might be right for
Fibromuscular DysplasiaEarly Onset CAD
Icahn School of Medicine at Mount Sinai 34
Large-scale testing (Phase 3)Looking for participantsNCT07157774
What this trial is testing

Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)

Who this might be right for
Elevated Lp(a)Atherosclerotic Cardiovascular Disease (ASCVD)
Eli Lilly and Company 10,450
Not applicableLooking for participantsNCT06936111
What this trial is testing

REsiduAL rISk Under Intensive Lipid-lowering Therapy In Coronary Heart Disease

Who this might be right for
Coronary Heart Disease (CHD)
Shanghai Zhongshan Hospital 900
Testing effectiveness (Phase 2)Study completedNCT00570752
What this trial is testing

Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis

Who this might be right for
Vascular Diseases
Bristol-Myers Squibb 72
Not applicableActive Not RecruitingNCT05462262
What this trial is testing

Intensive Lipid-lowering for Plaque and Major Adverse Cardiovascular Events in Low to Intermediate 10-year ASCVD Risk Population

Who this might be right for
Coronary Artery Disease Progression
Chinese Academy of Medical Sciences, Fuwai Hospital 2,900
Next Page